The Nasdaq and Hong Kong Stock Exchange-listed company is dedicated to becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.
From its new location in Basel, BeiGene will manage its European clinical trial operations and prepare for the potential launch of its drug candidates outside of Asia. The new presence marks another milestone for BeiGene on its way to becoming a leading global bio-pharma company.
Access to a large and highly skilled talent pool, a business-friendly environment and close proximity to the European market were key drivers of BeiGene’s decision to establish operations in Basel. Basel is home to several of the world’s leading oncology companies and a vibrant biotech hub. Many global life sciences companies manage their commercial activities from Basel.
BeiGene has a global team of over 1,300 employees, including more than 500 people in its clinical team in China, the United States and Australia. The company has offices in China in Beijing, Guangzhou, Shanghai and Suzhou; in the United States in Cambridge, MA, Ridgefield Park, NJ, and Emeryville and San Mateo, CA; and in Europe in Basel, Switzerland.
